We want to help plan sponsors understand that cohort and build benefits around it, not just to reduce the likelihood of a stroke or heart attack, but to advance benefits equity within their plans
Well, hello, BPC 157 the darling child of the optimized self, bodybuilding and performance enhancing communities
The SURMOUNT-3 trial had 806 obese adults without T2D undergo 12 weeks of intensive lifestyle intervention, before randomizing the 579 participants who lost 5% of their body weight to receive either tirzepatide or a placebo
J.SpeyerE.BuiL.ChamleyP.et al (2019)
TIRZEPATIDE Semaglutide is the well-established GLP-1 medication
Patients with GI sensitivity: While orforglipron's GI side effect profile is broadly similar to injectable GLP-1s, the daily oral dosing means the GI tract is exposed to the active compound on a different kinetic schedule than weekly injections